Metraipolis › archive › dc_6ea0ee556e71
Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD) — Europe PMC PMID:41053100
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41053100
- DOI
- 10.1038/s41419-[numero omesso]-0
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T13:46:35.153Z
- SHA-256 of the archived text
5870b9e95e4a2a86dfeb9c19c5be2876daff3e9e7a737f1a18128c9a8e8982ec- Stable URL of this page
https://metraipolis.com/documento/dc_6ea0ee556e71
How to cite
Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD) — Europe PMC PMID:41053100 — Europe PMC (en), https://europepmc.org/article/MED/41053100 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6ea0ee556e71 (Metraipolis archive dc_6ea0ee556e71, sha256 5870b9e95e4a2a86dfeb9c19c5be2876daff3e9e7a737f1a18128c9a8e8982ec)
BibTeX
@misc{dc6ea0ee556e71,
title = {Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD) — Europe PMC PMID:41053100},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41053100},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6ea0ee556e71; sha256 5870b9e95e4a2a86dfeb9c19c5be2876daff3e9e7a737f1a18128c9a8e8982ec},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41053100. Agents can read the archived copy with the MCP tool read_document.